Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 5/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23802550 | 0.94 | MEN1 (0.35) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL17771615 | 0.86 | MEN1 (0.37) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL14190505 | 0.82 | MEN1 (0.46) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL26703793 | 0.81 | TDP1 (0.33) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL23802552 | 0.81 | CYP1A2 (0.40) | MEN1GAAKMT2ACA1CTSK | |
| SCHEMBL24296988 | 0.81 | MEN1 (0.39) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL14190506 | 0.81 | MEN1 (0.45) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL23802553 | 0.80 | CA12 (0.36) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL23802557 | 0.80 | TDP1 (0.47) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL18349774 | 0.79 | HDAC8 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4584256-A1 | MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | Philochem AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024052333-A1 | MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2024-03-14 | — | — | WO | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2023015223-A9 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023015223-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-11207416-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210299261-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20030199577-A1 | Substrate with controlled amine density and regular spacing and method for preparing the same | POSTECH FOUNDATION (KR) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | MEN1 688/4885GAA 4537/4885KMT2A 1938/4885 |
| US-20030199577-A1 | Substrate with controlled amine density and regular spacing and method for preparing the same | ADRA1B, ADRA1D, CYP4Z1 | MEN1 2225/4885GAA 2287/4885KMT2A 1119/4885 |
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | MEN1 3813/4885GAA 264/4885KMT2A 1385/4885 |
| US-11207416-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | MEN1 3813/4885GAA 264/4885KMT2A 1385/4885 |
| US-20210299261-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | MEN1 3813/4885GAA 264/4885KMT2A 1385/4885 |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | MEN1 3813/4885GAA 264/4885KMT2A 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.